Evidence map›Paper›PMID 32896928›Full record

Observational studyClinical cardiology2020

Impact of gender: Rivaroxaban for patients with atrial fibrillation in the XANTUS real-world prospective study.

A John Camm, Pierre Amarenco, Sylvia Haas, Miriam Bach, Paulus Kirchhof, Silvia Kuhls, Marc Lambelet, Alexander G G Turpie, XANTUS Investigators

Registry-linked trialOpen access · goldAbstract readComparative StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical cardiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01606995 (Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.1field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01606995 completednot on this map

Xarelto® on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation

TypeobservationalSponsorBayerRan2012 to 2015Enrolled6,784ConditionsAtrial FibrillationArmsRivaroxaban (Xarelto, BAY59-7939)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Refining the CHA2DS2VASc risk stratification scheme: shall we drop the sex category criterion?Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2024
    Article
  2. Article
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 5 countries.

A John CammCardiovascular and Cell Sciences Research Institute, St George's, University of London, London, UK.ORCID https://orcid.org/0000-0002-2536-2871
Pierre AmarencoDepartment of Neurology and Stroke Centre, Paris-Diderot-Sorbonne University, Paris, France.
Sylvia HaasFormerly Technical University Munich, Munich, Germany.
Miriam BachMedical Affairs, Bayer AG, Berlin, Germany.
Paulus KirchhofInstitute of Cardiovascular Sciences, University of Birmingham, University Hospital Birmingham NHS Foundation Trust and Sandwell and West Birmingham Hospitals NHS Trust, Birmingham, UK.ORCID https://orcid.org/0000-0002-1881-0197
Silvia KuhlsIntegrated Analysis Statistics, Bayer AG, Wuppertal, Germany.
Marc LambeletChrestos Concept GmbH and Co KG, Essen, Germany.
Alexander G G TurpieDepartment of Medicine, McMaster University, Hamilton, ON, Canada.
XANTUS Investigators
Bayer (Germany) · DEDélégation Paris 7 · FRDeutsche Montan Technologie (Germany) · DEMcMaster University · CASt George's, University of London · GBTechnical University of Munich · DEUniversity Hospitals Birmingham NHS Foundation Trust · GB

Funding

BayerJanssen Research and Development
6 · The paper itself

Abstract

backgroundThe XANTUS study (NCT01606995) demonstrated low rates of stroke and major bleeding in patients with atrial fibrillation (AF) receiving rivaroxaban in clinical practice for the prevention of thromboembolic events (N = 6784). HYPOTHESIS: Because previous real-world studies have not reported gender-dependent responses to rivaroxaban treatment, this sub-analysis of the XANTUS study investigated the effect of gender on outcomes.

methodsThe centrally adjudicated outcomes were compared between genders. Primary outcomes were major bleeding and all-cause death. Secondary outcomes included symptomatic thromboembolic events. Multivariable Cox regression analysis was performed to assess the effect of risk factors on outcomes between genders.

resultsA total of 2765 female and 4016 male patients were included in the analysis. Baseline characteristics were generally similar. No nominally significant interaction between gender and risk factors for the study outcomes was observed. Rates of major bleeding, all-cause death and symptomatic thromboembolic events in patients with non-valvular AF receiving rivaroxaban for stroke prevention were similar in men and women; no significant differences in risk factors for these outcomes were observed between genders.

conclusionsFurther research is needed to better characterize the relative importance of different risk factors on outcomes in men vs women and to determine whether gender differences exist in patients treated with non-vitamin K antagonist oral anticoagulants.

Indexed as

AgedAtrial FibrillationDose-Response Relationship, DrugEuropeFactor Xa InhibitorsFemaleHumansIncidenceMaleProspective StudiesRisk AssessmentRisk FactorsRivaroxabanSex DistributionSex FactorsSurvival RateFactor Xa InhibitorsRivaroxabananticoagulantatrial fibrillationreal-world evidencestroke

Identifiers

PMID32896928
PMCPMC7724214
OpenAlexW3083887769

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.